-
Alliance centralized procurement "speed-up and expansion" hammer!
Time of Update: 2022-05-12
. From the perspective of the key varieties promoted by the centralized procurement of various alliances, drugs have been extended from chemical drugs to traditional Chinese medicines, and the variety of medical equipment has been expanded, involving oral implants, electrophysiology and endoscopic staplers, new crown-related testing reagents and consumables, liver function Biochemical reagents, etc.
-
"Regulations on the Administration of Drug Annual Reports" will come into effect on April 12
Time of Update: 2022-05-12
According to the requirements of the "Drug Administration Law", drug marketing license holders shall establish an annual reporting system, and report the production and sales of drugs, post-marketing research, and risk management to the drug regulatory department in accordance with regulations .
-
The first imitation of large varieties was approved intensively, and who is the first among Chia Tai Tianqing, Hengrui, Qilu and Yangzijiang
Time of Update: 2022-05-12
With the shift of business focus to innovative drugs, leading companies such as Chia Tai Tianqing, Hengrui, and Qilu are still in the forefront in the number of first copy approvals .
-
An overview of the drug administration policies in the first quarter, these changes are closely related to you!
Time of Update: 2022-05-12
In this regard, the "Regulations on the Supervision and Administration of Cosmetics", which will take effect on January 1, 2021, clearly implements the standard system for the quality management of cosmetic production, and imposes corresponding penalties for those who do not organize production and self-inspection as required .
-
The total R&D investment of 51 pharmaceutical companies exceeds 40.8 billion yuan, and these four companies all exceed 3 billion yuan
Time of Update: 2022-05-12
Among them, four listed companies including Hengrui Medicine, Fosun Pharma, China Biopharmaceuticals, and CSPC have invested more than 3 billion yuan in research and development .
-
Baiji, Cinda, Tianqing... More than 10 domestic companies are deployed, PI3K inhibitors are about to face the FDA exam tonight
Time of Update: 2022-05-12
cn/v5/home/) * The visualization function of the Insight database can easily view the progress trend of specific targets/indications/component categories in China and even in the world at each stage, and clearly grasp the research and development status of new drug projects in the field of interest.
-
The head of Novartis Innovative Drugs China confirmed!
Time of Update: 2022-05-12
Novartis business "two-in-one" innovative drug China head confirmed In the past two years, multinational pharmaceutical companies have set off a new round of organizational restructuring, with frequent personnel changes .
-
257 drug price adjustments, 277 into the price linkage catalog!
Time of Update: 2022-05-12
According to the requirements, the national emergency (rescue), pediatric generic drug demonstration catalog drugs, and shortage drugs, the manufacturer independently applies for listing and provides the lowest current online (transaction) price of the drug in the three provinces in the country, as a reference for medical institutions to negotiate, and Implement dynamic management according to relevant policies and the situation of hanging on the network .
-
First imitation!
Time of Update: 2022-05-12
From : CDE official website Dolutegravir (DTG) is an anti-AIDS drug developed by GlaxoSmithKline/ViiV, which is an integrase inhibitor .
According to the Insight database, there are currently 3 combination preparations of dolutegravir that have been approved for the market in addition to single drugs worldwide .
-
Double Anti-New Deal for comments!
Time of Update: 2022-05-12
In China, Roche's double-antibody aceprin was approved as the first double-antibody drug in 2018; Amgen/BeiGene's belintuo double-antibody drug was approved for marketing at the end of 2020, including Acupuncture, Corning Jerry, Enterprises such as Innovent Bio, BeiGene, Henlius and other companies came one after another, opening a new pattern of dual resistance .
-
Chinese medicine companies that invest more than 100 million yuan in research and development, is the money used correctly?
Time of Update: 2022-05-12
Table 1: Some listed Chinese medicine companies with R&D investment of over 100 million yuan (Data source: corporate annual report) CDE data shows that in 2021, CDE accepted a total of about 1,360 traditional Chinese medicines, including 60 new drug applications.
-
Guotan Pharmaceutical "Dual Channel" Management Adjustment!
Time of Update: 2022-05-12
On April 26, the Jiangsu Provincial Medical Security Bureau issued the "Notice on Adjusting the "Dual Channel" Management and Separate Payment of Some Guotan Drugs" (for details, please click to read the original text ), and 8 Guotan drugs such as Trastuzumab Injection were issued.
-
Notice on "The 88th API China is postponed to August 3-5"
Time of Update: 2022-05-12
Dear exhibitors, visitors and industry friends: Thank you for your attention and support to "China International Pharmaceutical API/Intermediate/Packaging/Equipment Fair (hereinafter referred to
-
The market for many medicinal materials is sluggish and the sales are not good
Time of Update: 2022-05-11
Merchants in the Anguo market have paid less attention recently, the supply of goods is in a normal state of purchase and sales, and the market remains stable compared to the previous period.
-
Explore the depths of digitalization!
Time of Update: 2022-05-11
At the Smart Water Summit Forum, industry insiders talked about intelligent operation to management, from intelligent drainage to pump products, as well as multi-dimensional analysis and detailed explanations such as filtration and monitoring .
-
The performance of pharmaceutical and biological companies has been exposed, and the net profit of eight pharmaceutical companies has increased by over 100%
Time of Update: 2022-05-11
02% year-on-year, about 148 million yuan; during the reporting period , Jimin Medical, in order to meet the market demand, the company's wholly-owned subsidiary Jumin Bio has newly invested in the construction of 4 production lines for safety syringes (needles).
-
R&D is not easy, and strong alliances have become the general trend of the pharmaceutical industry
Time of Update: 2022-05-11
Recently, Bristol-Myers Squibb and Nektar Therapeutics announced that they have decided to close the pre-planned analysis of two late-stage clinical studies of bempegaldesleukin in combination with Opdivo (nivolumab) in renal cell carcinoma and bladder cancer.
-
The "back wave" of the medical imaging equipment market is catching up with a strong momentum, and another company will pass!
Time of Update: 2022-05-11
[Pharmaceutical Network Industry News] For a long time, China's high-end medical imaging equipment market has been monopolized by foreign companies, and imported products account for more than 90% of the market .
-
Carried out!
Time of Update: 2022-05-11
[Pharmaceutical Network Conference Forum] It has been long-awaited, and today (April 12), the 2022 SIGHT Spring Exhibition finally started! The newly upgraded 3D exhibition hall will bring you an imm
-
A large number of pharmaceutical companies are working together to develop innovative treatments for PD
Time of Update: 2022-05-11
In recent years, based on the huge patient population and treatment needs, many pharmaceutical companies have begun to deploy in this field .
The industry believes that the submission of Safinamide Tablets for listing in China this time is expected to bring new options for innovative therapies and drugs to domestic patients .
